ArticleThe Journal of international medical research2025
Neural epidermal growth factor-like 1 expression predicts end-stage renal disease in phospholipase A2 receptor-negative membranous nephropathy: A retrospective cohort stratified by systemic lupus erythematosus.
Article in The Journal of international medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Quantitative serological detection of NELL1 autoantibodies in membranous nephropathy.Kidney international · 2026Article
- Artificial intelligence in healthcare: Clinical decision making algorithms, evidence-based applications, future insights, and beyond.The Journal of international medical research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BackgroundNeural epidermal growth factor-like 1 protein has emerged as a significant antigen in membranous nephropathy, an important cause of nephrotic syndrome in adults. However, the prognosis of neural epidermal growth factor-like 1-associated membranous nephropathy remains limited and requires further exploration.MethodsA Chinese retrospective cohort of 446 patients diagnosed with membranous nephropathy on renal biopsy was categorized into phospholipase A2 receptor-associated (n = 358) and phospholipase A2 receptor-negative (n = 88) membranous nephropathy groups. The phospholipase A2 receptor-negative group was subjected to neural epidermal growth factor-like 1 fluorescence staining. Multivariate regression analyses, stratified analyses, and Kaplan-Meier analyses were used to explore the correlation of neural epidermal growth factor-like 1 with the risk of end-stage renal disease.ResultsWe identified 11 cases of neural epidermal growth factor-like 1-associated membranous nephropathy, accounting for 12.7% of phospholipase A2 receptor-negative membranous nephropathy cases. These patients were predominantly young women with a history of fairness cream use. In patients with phospholipase A2 receptor-negative membranous nephropathy, multivariable regression analysis showed that the neural epidermal growth factor-like 1-positive group had a higher risk of end-stage renal disease compared with the neural epidermal growth factor-like 1-negative group (hazard ratio = 3.2, p = 0.026). Stratified analysis showed that this association was particularly significant in patients with systemic lupus erythematosus (hazard ratio = 5.1, p = 0.041). Kaplan-Meier analysis also revealed a higher risk in neural epidermal growth factor-like 1-positive patients (p = 0.003).ConclusionNeural epidermal growth factor-like 1 expression is an independent risk factor for end-stage renal disease, especially in patients with systemic lupus erythematosus, with an incidence rate of approximately 12.7% in patients with phospholipase A2 receptor-negative membranous nephropathy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.